Trial Profile
Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Cancer
- Focus Therapeutic Use
- 20 Nov 2023 Status changed from active, no longer recruiting to discontinued.
- 01 May 2023 Results published in the Clinical Cancer Research
- 17 May 2022 Planned End Date changed from 1 Sep 2021 to 1 Sep 2022.